HSIC · NMS · Healthcare
Henry Schein, Inc.
Also onShortfallConsensus DriftCrosscheck
Implied value per share
USD 62.05
Market price
USD 84.84
Implied upside
-26.9%
5-year forecast · Perpetuity growth terminal value · Mid-year discounting · Base case
Value Per Share
Same forecast, different terminal treatment. Percentages vs price.
Forecast Cashflows
Reporting currency (USD). Outflows negative.
| Line | FY26 | FY27 | FY28 | FY29 | FY30 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | USD 13.4bn | USD 13.6bn | USD 13.7bn | USD 13.9bn | USD 14.1bn | +1.4% |
| EBIT | USD 805.2m | USD 816.4m | USD 827.8m | USD 839.4m | USD 851.1m | +1.4% |
| NOPAT | USD 636.1m | USD 645.0m | USD 654.0m | USD 663.1m | USD 672.3m | +1.4% |
| Add depreciation & amortisation | USD 253.3m | USD 256.8m | USD 260.4m | USD 264.1m | USD 267.7m | +1.4% |
| Less capital expenditure | USD -182.2m | USD -184.7m | USD -187.3m | USD -189.9m | USD -192.6m | +1.4% |
| Less increase in working capital | USD 77.1m | USD 78.2m | USD 79.3m | USD 80.4m | USD 81.5m | -1.4% |
| Free cashflow to firm | USD 784.3m | USD 795.3m | USD 806.4m | USD 817.6m | USD 829.0m | +1.4% |
| Discount factor | 0.9612 | 0.8880 | 0.8203 | 0.7579 | 0.7001 | - |
| Present value | USD 753.9m | USD 706.2m | USD 661.5m | USD 619.6m | USD 580.4m | -6.3% |
| Present Value Of The Forecast | USD 3.3bn | |||||
Discount Rate
Source shown per component. All overridable above.
| Risk-free rate | 5.00% | US 10-year Treasury (^TNX) |
| Equity risk premium | 5.50% | Market assumption |
| Beta | 0.874 | Reported 0.812, pulled toward 1.0 (Blume) |
| Cost of equity | 9.81% | Risk-free + beta x equity risk premium |
| Cost of debt | 5.00% | Floored at the risk-free rate (implied cost of debt was lower) |
| Market capitalisation | USD 9.5bn | 73.3% of capital |
| Total debt | USD 3.4bn | 26.7% of capital, book value as a proxy |
| Tax rate | 21.0% | Effective, capped at statutory |
| WACC | 8.24% | E/V x Re + D/V x Rd x (1 - t) |
Terminal Value
Perpetuity growth is intrinsic. The exit multiple defaults to the company's current EV/EBITDA, so it answers a different question - what the shares are worth if today's rating holds and EBITDA grows as forecast.
Perpetuity growth at 2.50%
69% of EV
- Forecast FCFF, final year
- USD 829.0m
- Capex at depreciation, working capital in reinvestment
- USD 813.4m
- Less reinvestment at g/ROIC (26.1% of NOPAT)
- USD -212.2m
- Capitalised
- USD 601.2m
- ROIC (reported)
- 9.6%
- Terminal value, undiscounted
- USD 10.7bn
- Terminal value, discounted
- USD 7.5bn
- Enterprise value
- USD 10.8bn
- Less net debt
- USD 3.3bn
- Equity value
- USD 7.6bn
Exit at 12.3x EBITDA
74% of EV
- Terminal value, undiscounted
- USD 13.7bn
- Terminal value, discounted
- USD 9.6bn
- Enterprise value
- USD 12.9bn
- Less net debt
- USD 3.3bn
- Equity value
- USD 9.6bn
Spread between methods: 24%.
Sensitivity
Value per share (USD) by discount rate and long-run growth.
| Long-run growth | |||||
|---|---|---|---|---|---|
| Discount rate | 1.50% | 2.00% | 2.50% | 3.00% | 3.50% |
| 6.24% | 93.41 | 98.35 | 104.54 | 112.56 | 123.41 |
| 7.24% | 73.66 | 76.03 | 78.85 | 82.28 | 86.55 |
| 8.24% | 59.73 | 60.82 | 62.05 | 63.47 | 65.14 |
| 9.24% | 49.38 | 49.77 | 50.18 | 50.62 | 51.10 |
| 10.24% | 41.88 | 42.09 | 42.30 | 42.51 | 42.72 |
Outlined: this model. Green text: above today's price of 84.84. Shading: distance from this model's own value.
Priced In
What each input would have to be to justify the current price, one at a time.
| Input | Model | Implied | Gap |
|---|---|---|---|
| Revenue growth, every year | 1.4% | 5.1% | +3.7pp |
| EBIT margin | 6.0% | 7.9% | +1.9pp |
| Discount rate | 8.2% | 7.0% | -1.3pp |
Live formulas, not pasted numbers - edit a driver and the workbook reprices.
Yahoo Finance and RBA data. General information, not advice. Methodology.